Regulations.gov document
Determination That RIFADIN (Rifampin) Capsules, 150 Milligrams and 300 Milligrams, Were…
Notice · FDA-2024-P-5470 · posted Aug 19, 2025
Key facts
| Document ID | FDA-2024-P-5470-0004 |
|---|---|
| Title | Determination That RIFADIN (Rifampin) Capsules, 150 Milligrams and 300 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness |
| Document type | Notice |
| Subtype | Determinations |
| Agency | FDA |
| Docket | FDA-2024-P-5470 |
| Posted | Aug 19, 2025 |
| Federal Register citation | 90 FR 40373 |
| FR document number | 2025-15786 |
| Comment period opens | Aug 19, 2025 |
| Effective date | Aug 19, 2025 |
At a glance
- 1–9 Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: